Simponi (golimumab) is a new option for treating ulcerative colitis in adults

Simponi (golimumab) is a new option for treating ulcerative colitis in adults.

It's already indicated for use in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Simponi is the second tumour necrosis factor (TNF) blocker approved for ulcerative colitis after Remicade (infliximab).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote